FibroGen (NASDAQ:FGEN) Stock Price Crosses Above 50 Day Moving Average of $1.70

Shares of FibroGen, Inc. (NASDAQ:FGEN) passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $1.70 and traded as high as $1.74. FibroGen shares last traded at $1.37, with a volume of 34,107,993 shares.

Analyst Upgrades and Downgrades

Separately, William Blair reiterated a “market perform” rating on shares of FibroGen in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating and four have issued a hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $17.00.

FibroGen Price Performance

The company’s 50-day simple moving average is $1.70 and its two-hundred day simple moving average is $1.24. The firm has a market capitalization of $136.27 million, a P/E ratio of -0.47 and a beta of 0.88.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.15). The firm had revenue of $27.14 million during the quarter, compared to analysts’ expectations of $40.00 million. Analysts predict that FibroGen, Inc. will post -1.09 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Thane Wettig acquired 50,000 shares of the stock in a transaction dated Thursday, March 7th. The shares were purchased at an average cost of $1.91 per share, with a total value of $95,500.00. Following the transaction, the chief executive officer now directly owns 470,178 shares in the company, valued at $898,039.98. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.98% of the company’s stock.

Institutional Trading of FibroGen

Several institutional investors and hedge funds have recently modified their holdings of FGEN. Mackenzie Financial Corp boosted its holdings in FibroGen by 112.6% in the 3rd quarter. Mackenzie Financial Corp now owns 51,490 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 27,275 shares during the period. Fox Run Management L.L.C. purchased a new position in shares of FibroGen in the third quarter valued at about $37,000. Accel Wealth Management bought a new position in shares of FibroGen in the first quarter worth about $103,000. SG Americas Securities LLC grew its position in shares of FibroGen by 79.8% during the fourth quarter. SG Americas Securities LLC now owns 112,783 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 50,073 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of FibroGen during the third quarter worth about $45,000. 72.71% of the stock is currently owned by institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.